ZandCell

ZandCell is a privately held biotechnology company committed to bringing to market life-transforming therapeutics for patients with untreatable diseases. The company focuses on diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no current effective treatment modalities. The company is led by a management team experienced in the development and commercialization of disease therapeutics. ZandCell's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. The overall objective of ZandCell and its operations is to develop medical treatments in the fields of regenerative medicine, gene editing, and immunotherapy worldwide. Please visit: https://zandcell.com/ for more information.